Progesterone, hydrocortisone butyrate, and estrone base are discussed as treatments for hair loss. Topical progesterone and dutasteride are suggested to potentially reverse androgenic alopecia.
Pyrilutamide, a potential topical treatment for male pattern baldness, and the user's anticipation of its Phase 2 trial results. Several users discussed their experiences with Finasteride and RU58841, while others voiced skepticism about the efficacy of Pyrilutamide.
Two Chinese suppliers provided legitimate RU58841, confirmed through a free drug testing service. The vendors were Shaanxi Greenyo Biotech and Lyphar, found on Made-in-China.
The conversation is about finding a clearnet vendor for clascoterone, also known as Winlevi, for hair loss treatment. The user is seeking recommendations via direct message.
A user was prescribed a topical treatment for hair loss including Latanoprost, Minoxidil, Dutasteride, Hydrocortisone, and Progesterone, after using an oral Minoxidil and Finasteride combo without significant results. Concerns were raised about the long-term use of hydrocortisone, with suggestions to consult a doctor regularly.
The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.
Fluridil, an antiandrogen that is not widely used or known about due to its expense and lack of availability in the US. It is suggested as a potential alternative for people who don't want to lower their DHT through treatments such as Minoxidil, Finasteride, Nizoral shampoo, and Dermarolling.
Finasteride and dutasteride are discussed for hair loss, with concerns about their effects on neurosteroids and potential side effects like depression. Alternatives like topical estrogen and lifestyle changes are considered, with varying opinions on mental health and hair regrowth.
The user is using finasteride, HGH, GHK-CU, BPC-157, KPV, biotin/collagen/keratin vitamins, ketoconazole shampoo, and low-dose naltrexone to address hair loss, avoiding minoxidil due to past shedding experiences. Adenosine is discussed as a potential alternative to minoxidil, though it is noted to be expensive and hard to find.
The conversation discusses sourcing Topilutamide (fluridil) as a treatment for hair loss, with users comparing it to RU58841 and finasteride. Users share their experiences with various treatments, including testosterone, DHT gel, and Proviron, while expressing difficulty in finding Topilutamide.
The conversation discusses the effectiveness of RU58841 for hair loss compared to pyrilutamide, which failed to show significant hair regrowth in trials. Some users report personal side effects with RU58841 and question the criteria for success in hair loss treatments.
PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
User used sublingual minoxidil for 5 months and saw progress. Also used topical dutasteride, alfatradiol, tretinoin, and reduced oral finasteride dose.
Woman uses antiandrogens for hair thinning prevention, experiences severe dry eye with finasteride. Asks if dutasteride could be better despite potential for worse dry eye.
A new hair loss treatment called TDM-105795 is discussed as a potential replacement or add-on to Minoxidil. Users express hope for new effective treatments.
The user is seeking a substitute for Tretinoin to enhance the effectiveness of Minoxidil for hair loss. They are considering using Retinol as an alternative.
The user received a Fagron TrichoTest indicating that Finasteride, Dutasteride, and Minoxidil are not effective for them, recommending Latanoprost, Spironolactone, IGrantine-F1 TM, and Trichoxidil instead. Other users expressed skepticism about the test's validity and suggested sticking with proven treatments like Finasteride and Dutasteride.
The user has been using Pyrilutamide (Pyril) for hair loss for a month alongside finasteride/dutasteride since 2021 but hasn't seen results. They are considering switching to RU58841 due to its many success stories, despite being skeptical about the legitimacy and testing of Pyrilutamide.
User is using minoxidil with tretinoin 0.025% and experiencing peeling and burning on the scalp. They are unsure if it's effective or if they are using it too frequently.
The conversation discusses arranging an interview with the developers of RU58841 to clarify its safety and reasons for halted research, with some users expressing concerns about potential risks and others citing financial reasons for the discontinuation of studies. Specific treatments mentioned include RU58841, minoxidil, and finasteride.
The conversation is about using PTD-DBM and valproic acid for hair loss. The user is inquiring about the dosage of these treatments, noting that valproic acid is used at a 7.5% solution.
Veradermics' extended-release oral minoxidil is expected to be commercially available in 2027-2028, while another company, Minx, may release a similar product sooner. VDPHL01 is considered more clinically validated compared to Minx.
Chinese company gets green light for Pyrilutamide Phase II trial for androgenetic alopecia. Androgen receptors downregulate in androgen deficient environments.
The conversation is about accessing and purchasing RU58841 or Pyrilutamide for hair loss treatment, with mentions of alternatives like Breezula. Users discuss price differences in various countries and suggest websites like rudirect.com for purchasing.
PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.
Hair loss treatments RU55841, CB-03-01, and Eucapil were discussed, with concerns about needing increased dosages over time and potential side effects. A user suggested that CB's results could be due to various factors and that combining it with finasteride might slow down any upregulation.
User asks if spironolactone can stack with finasteride and pyrilutamide for hair loss treatment. They question why spironolactone is associated with feminizing effects, while RU/pyri/fluridil, which work similarly, are not.
The conversation is about the effectiveness of Fluridil (Eucapil) for hair loss compared to RU58841, with the original poster considering Fluridil a safer and potentially more effective alternative.